Literature DB >> 33474694

Performance of cardiac PET/CT with and without phase analysis for detection of scar in cardiac sarcoidosis: Comparison to cardiac magnetic resonance imaging.

Mohamed Y Elwazir1,2, Jared G Bird1, Omar F AbouEzzeddine1, Panithaya Chareonthaitawee1, Lori A Blauwet1, Jeremy D Collins3, Raymond J Gibbons1, Martin Rodriguez-Porcel1, Hanan M Kamal2, Ahmed T Abdellah2, John P Bois4.   

Abstract

BACKGROUND: The presence of myocardial scar in CS patients results in poor prognosis and worse outcomes. 18F-fluorodeoxyglucose (18F-FDG) PET/CT excels at visualizing inflammation but is suboptimal at detecting scar. We evaluated PET/CT sensitivity to detect scar and investigated the incremental diagnostic value of automated PET-derived data.
METHODS: 176 patients who underwent cardiac magnetic resonance (CMR) and N-13 ammonia/18F-FDG cardiac PET/CT for suspected CS within 3 months were enrolled. Scar was defined as late gadolinium enhancement (LGE) on CMR without concordant 18F-FDG uptake on 18F-FDG PET/CT. Accuracy of cardiac PET/CT at detecting scar (perfusion defect without concordant 18F-FDG uptake) was assessed before and after addition of automated PET-derived data.
RESULTS: Sensitivity of PET/CT for scar detection was 45.3% (specificity 88.9%). Addition of PET-derived LV volumes and function in a logistic regression model improved sensitivity to 57.0% (specificity: 80.0%, AUC 0.72). Addition of phase analysis maximum segmental onset of myocardial contraction > 61 improved AUC to 0.75, correctly relabeling 16.3% of patients as scar (net reclassification index 8.2%).
CONCLUSION: Sensitivity of gated PET MPI alone for scar detection in CS is suboptimal. Adding PET-derived volumes/function and phase analysis data results in improved detection and characterization of scar.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Inflammation; MPI; MRI; Metabolic; PET; Sarcoid heard disease

Mesh:

Substances:

Year:  2021        PMID: 33474694     DOI: 10.1007/s12350-020-02473-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  3 in total

1.  Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis.

Authors:  Shinji Ishimaru; Ichizo Tsujino; Shinji Sakaue; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Nagara Tamaki; Masaharu Nishimura
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2005-10       Impact factor: 0.670

Review 2.  Cardiac sarcoidosis-state of the art review.

Authors:  Edward Hulten; Saira Aslam; Michael Osborne; Siddique Abbasi; Marcio Sommer Bittencourt; Ron Blankstein
Journal:  Cardiovasc Diagn Ther       Date:  2016-02

3.  Diagnostic value of (18)F-FDG PET in the assessment of myocardial viability in coronary artery disease: A comparative study with (99m)Tc SPECT and echocardiography.

Authors:  Mansour Al Moudi; Zhong-Hua Sun
Journal:  J Geriatr Cardiol       Date:  2014-09       Impact factor: 3.327

  3 in total
  1 in total

Review 1.  Advances in Diagnostic Imaging for Cardiac Sarcoidosis.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Tadao Aikawa; Satonori Tsuneta; Nagara Tamaki
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.